174 related articles for article (PubMed ID: 34800542)
21. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
22. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
[TBL] [Abstract][Full Text] [Related]
23. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
[TBL] [Abstract][Full Text] [Related]
25. Expression of the primary angle closure glaucoma (PACG) susceptibility gene PLEKHA7 in endothelial and epithelial cell junctions in the eye.
Lee MC; Chan AS; Goh SR; Hilmy MH; Nongpiur ME; Hong W; Aung T; Hunziker W; Vithana EN
Invest Ophthalmol Vis Sci; 2014 May; 55(6):3833-41. PubMed ID: 24801512
[TBL] [Abstract][Full Text] [Related]
26. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
27. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
28. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression.
Chen M; Lin M; Wang X
Oncol Rep; 2018 Feb; 39(2):619-626. PubMed ID: 29207158
[TBL] [Abstract][Full Text] [Related]
30. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Najumudeen AK; Ceteci F; Fey SK; Hamm G; Steven RT; Hall H; Nikula CJ; Dexter A; Murta T; Race AM; Sumpton D; Vlahov N; Gay DM; Knight JRP; Jackstadt R; Leach JDG; Ridgway RA; Johnson ER; Nixon C; Hedley A; Gilroy K; Clark W; Malla SB; Dunne PD; Rodriguez-Blanco G; Critchlow SE; Mrowinska A; Malviya G; Solovyev D; Brown G; Lewis DY; Mackay GM; Strathdee D; Tardito S; Gottlieb E; ; Takats Z; Barry ST; Goodwin RJA; Bunch J; Bushell M; Campbell AD; Sansom OJ
Nat Genet; 2021 Jan; 53(1):16-26. PubMed ID: 33414552
[TBL] [Abstract][Full Text] [Related]
31. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
32. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
[TBL] [Abstract][Full Text] [Related]
33. Modulating Pluripotency Network Genes with Omega-3 DHA is followed by Caspase- 3 Activation and Apoptosis in DNA Mismatch Repair-Deficient/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
Mahmoudi N; Delirezh N; Sam MR
Anticancer Agents Med Chem; 2020; 20(10):1221-1232. PubMed ID: 32116204
[TBL] [Abstract][Full Text] [Related]
34. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Barni S
Med Oncol; 2013; 30(3):650. PubMed ID: 23828442
[TBL] [Abstract][Full Text] [Related]
35. PLEKHA7, an Apical Adherens Junction Protein, Suppresses Inflammatory Breast Cancer in the Context of High E-Cadherin and p120-Catenin Expression.
Pence LJ; Kourtidis A; Feathers RW; Haddad MT; Sotiriou S; Decker PA; Nassar A; Ocal IT; Shah SS; Anastasiadis PZ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525380
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of
Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
[TBL] [Abstract][Full Text] [Related]
37. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
38. SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
Sameer AS; Chowdri NA; Syeed N; Banday MZ; Shah ZA; Siddiqi MA
BMC Cancer; 2010 Jun; 10():300. PubMed ID: 20565773
[TBL] [Abstract][Full Text] [Related]
39. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
Sarkhosh-Inanlou R; Imani M; Sam MR
Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
[TBL] [Abstract][Full Text] [Related]
40. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
Trinidad AG; Whalley N; Rowlinson R; Delpuech O; Dudley P; Rooney C; Critchlow SE
Oncogene; 2017 Nov; 36(44):6164-6176. PubMed ID: 28692044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]